Back to results

High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients

Objective

To evaluate the effect of high-dose vitamin D (HDVD) supplementation in prostate cancer patients on ADT-induced bone mineral density loss in the total hip over 52 weeks as measured by dual-energy x-ray absorptiometry (DXA).

Protocol #

URCC-22053

Trial Phase:

Phase III

Principal Investigator:

Paul, Asit

Cancer Type
  • Prostate
Study Site
  • Stony Point
  • Virginia Commonwealth University

Be diagnosed with Stage I-IV prostate cancer without metastases to bone (lymph node involvement and prior diagnosis of a primary cancer is allowed).
Be age 60 years or older.
Be starting ADT or have received their first ADT treatment in the past 3 months, with at least 6 planned months of treatment remaining (both luteinizing hormone-
releasing hormone (LHRH) antagonists and LHRH agonists are permitted).

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Supportive Care
  • Research Study Team Tyler Phillips
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: